Literature DB >> 3093565

In vivo thymocyte maturation. BUdR labeling of cycling thymocytes and phenotypic analysis of their progeny support the single lineage model.

C Penit.   

Abstract

Spontaneously cycling thymocytes have been labeled in vitro and in vivo by bromodeoxyuridine (BUdR), a non-reutilized precursor of DNA that is detectable by a monoclonal antibody. Studies of BUdR-labeled cells have included the determination of their anatomical location, size, and nuclear aspects and of their cell surface phenotype. Dividing blasts were initially located in the cortex (mainly but not exclusively in the subcapsular region) and expressed the double-negative (Lyt-2- L3T4-) and double-positive (Lyt-2+ L3T4+) phenotypes. The fate of these cells have been determined in days after BUdR administration, and we observed an initial double-negative to double-positive transition that was followed by the death of the majority of labeled cells in the cortex. As of day 3, the few surviving cells acquired a mature helper phenotype (Lyt-2- L3T4+) and began migrating into the thymic medulla. The exclusive medullary location of blast cell progeny was observed between days 5 and 10 post-BUdR administration. These results suggest a direct precursor-product relationship between dividing cortical cells and mature medullary thymocytes, and therefore support the single lineage model of intrathymic differentiation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3093565

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

Review 1.  Questionable thymic nurse cell.

Authors:  M Pezzano; M Samms; M Martinez; J Guyden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

2.  Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice.

Authors:  Feng X Li; Jing W Zhu; Christopher J Hogan; James DeGregori
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

3.  Automatic search for model to simulate the differentiation of T lymphocytes within the thymus.

Authors:  L Buffat; J Y Mary
Journal:  Acta Biotheor       Date:  1992-09       Impact factor: 1.774

4.  CD45 enhances positive selection and is expressed at a high level in large, cycling, positively selected CD4+CD8+ thymocytes.

Authors:  C J Ong; J P Dutz; D Chui; H S Teh; J D Marth
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

5.  Kinetics of mature T-cell development in the thymus.

Authors:  M Egerton; R Scollay; K Shortman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

6.  Increased division of alpha beta TCR+ and gamma delta TCR+ intestinal intraepithelial lymphocytes after oral administration of cholera toxin.

Authors:  I Penney; P J Kilshaw; T T MacDonald
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

7.  Thymic nurse cells: division of thymocytes within complexes.

Authors:  R Brelińska
Journal:  Cell Tissue Res       Date:  1989-12       Impact factor: 5.249

8.  A timeline demarcating two waves of clonal deletion and Foxp3 upregulation during thymocyte development.

Authors:  Daniel Y Hu; Jin Y Yap; Rushika C Wirasinha; Debbie R Howard; Christopher C Goodnow; Stephen R Daley
Journal:  Immunol Cell Biol       Date:  2015-10-29       Impact factor: 5.126

9.  The organotin-induced thymus atrophy, characterized by depletion of CD4+ CD8+ thymocytes, is preceded by a reduction of the immature CD4- CD8+ TcR alpha beta-/low CD2high thymoblast subset.

Authors:  R H Pieters; M Bol; B W Lam; W Seinen; A H Penninks
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

10.  Recovery from chemically induced thymus atrophy starts with CD4- CD8- CD2high TcR alpha beta-/low thymocytes and results in an increased formation of CD4- CD8- TcR alpha beta high thymocytes.

Authors:  R H Pieters; M Bol; B W Lam; W Seinen; N Bloksma; A H Penninks
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.